Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Sugammadex, a 纬-cyclodextrin that encapsulates selectively steroidal neuromuscular blocking agents, such as rocuronium or
vecuronium, has changed the face of clinical neuromuscular pharmacology. Sugammadex allows a rapid reversal of muscle
paralysis. Sugammadex appears to be safe and well tolerated. Its blood-brain barrier penetration is poor (<3% in rats), and thus
no relevant central nervous toxicity is expected. However the blood brain barrier permeability can be altered under different
conditions (i.e., neurodegenerative diseases, trauma, ischemia, infections, or immature nervous system). Here we show that
clinically relevant sugammadex concentrations cause apoptotic/necrotic neuron death in primary cultures. Studies on the
underlying mechanism revealed that sugammadex-induced activation of mitochondria-dependent apoptosis associates with
depletion of neuronal cholesterol levels. Furthermore SUG increase CytC, AIF, Smac/Diablo and CASP-3 protein expression
in neurons in culture, related with mitochondrial activation pathway and increase in oxidative stress. On the other hand
rocuronium or vecuronium produced less damage caused by sugammadex alone.
Biography
Alma Casasempere is an MD, doing her PhD in the department of the Physiology. She is in the 3rd year and next will defense her thesis in the Hospital of La Fe.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals